IMPAIRMENT TO COST CAMBREX AT LEAST $85M

Cambrex Corp. said Thursday it will record an impairment charge of $85 million to $100 million in the fourth quarter of 2005. Cambrex stock fell 57 cents, closing at $21.43, on the news. Most of the impairment is within the Biopharma segment, resulting from unfavorable regulatory developments at a large client, the company said. The Biopharma segment will not break even in the quarter, Cambrex said.
North Jersey Media Group